Literature DB >> 32905290

Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia.

S Dolan1, A Christofides2, S Doucette2,3, M Shafey3.   

Abstract

Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually, 29-30 May. At the meeting, results from key studies about the treatment of chronic lymphocytic leukemia (cll) were disseminated. Studies examined the efficacy and safety of ibrutinib, acalabrutinib, zanubrutinib, and venetoclax as monotherapy or in combination with novel agents for patients with treatment-naïve and relapsed or refractory cll. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about potential effects on Canadian practice. 2020 Multimed Inc.

Entities:  

Keywords:  Chronic lymphocytic leukemia; refractory disease; relapsed disease; treatment-naïve disease; untreated disease

Mesh：

Substances：

Year:  2020        PMID： 32905290      PMCID： PMC7467799          DOI： 10.3747/co.27.7009

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  12 in total

1.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Authors:  Jan A Burger; Mariela Sivina; Nitin Jain; Ekaterina Kim; Tapan Kadia; Zeev Estrov; Graciela M Nogueras-Gonzalez; Xuelin Huang; Jeffrey Jorgensen; Jianling Li; Mei Cheng; Fong Clow; Maro Ohanian; Michael Andreeff; Thomas Mathew; Philip Thompson; Hagop Kantarjian; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Michael J Keating
Journal:  Blood       Date:  2018-12-07       Impact factor: 22.113

3.  Bcl-2 family members: Dual regulators of apoptosis and autophagy.

Authors:  Beth Levine; Sangita C Sinha; Guido Kroemer
Journal:  Autophagy       Date:  2008-07-01       Impact factor: 16.016

Review 4.  Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  C Owen; N L Berinstein; A Christofides; L H Sehn
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

5.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

6.  ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Paolo Ghia; Andrzej Pluta; Malgorzata Wach; Daniel Lysak; Tomas Kozak; Martin Simkovic; Polina Kaplan; Iryna Kraychok; Arpad Illes; Javier de la Serna; Sean Dolan; Phillip Campbell; Gerardo Musuraca; Abraham Jacob; Eric Avery; Jae Hoon Lee; Wei Liang; Priti Patel; Cheng Quah; Wojciech Jurczak
Journal:  J Clin Oncol       Date:  2020-05-27       Impact factor: 44.544

7.  Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn
Journal:  Lancet Oncol       Date:  2018-12-03       Impact factor: 41.316

8.  Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.

Authors:  Viralkumar Patel; Kumudha Balakrishnan; Elena Bibikova; Mary Ayres; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Clin Cancer Res       Date:  2016-12-29       Impact factor: 12.531

9.  Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.

Authors:  Tjeerd Barf; Todd Covey; Raquel Izumi; Bas van de Kar; Michael Gulrajani; Bart van Lith; Maaike van Hoek; Edwin de Zwart; Diana Mittag; Dennis Demont; Saskia Verkaik; Fanny Krantz; Paul G Pearson; Roger Ulrich; Allard Kaptein
Journal:  J Pharmacol Exp Ther       Date:  2017-09-07       Impact factor: 4.030

10.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Authors:  Martin Dreyling; Wojciech Jurczak; Mats Jerkeman; Rodrigo Santucci Silva; Chiara Rusconi; Marek Trneny; Fritz Offner; Dolores Caballero; Cristina Joao; Mathias Witzens-Harig; Georg Hess; Isabelle Bence-Bruckler; Seok-Goo Cho; John Bothos; Jenna D Goldberg; Christopher Enny; Shana Traina; Sriram Balasubramanian; Nibedita Bandyopadhyay; Steven Sun; Jessica Vermeulen; Aleksandra Rizo; Simon Rule
Journal:  Lancet       Date:  2015-12-07       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.